Eisenhauer E - Search Results

1

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.

Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. Chi KN, et al. Among authors: eisenhauer e. Clin Cancer Res. 2008 Feb 1;14(3):833-9. doi: 10.1158/1078-0432.CCR-07-1310. Clin Cancer Res. 2008. PMID: 18245546 Clinical Trial.

2

Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.

Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Chia S, et al. Clin Cancer Res. 2009 Jan 15;15(2):708-13. doi: 10.1158/1078-0432.CCR-08-1159. Clin Cancer Res. 2009. PMID: 19147778 Clinical Trial.

3

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Chi KN, et al. Among authors: eisenhauer ea. J Clin Oncol. 2010 Sep 20;28(27):4247-54. doi: 10.1200/JCO.2009.26.8771. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733135 Clinical Trial.

4

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. Among authors: eisenhauer e. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

5

A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.

Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. Tolcher AW, et al. Among authors: eisenhauer e. Clin Cancer Res. 2002 Aug;8(8):2530-5. Clin Cancer Res. 2002. PMID: 12171880 Clinical Trial.

6

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

Kollmannsberger C, Hirte H, Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Doyle A, Eisenhauer EA, Oza AM. Kollmannsberger C, et al. Among authors: eisenhauer ea. Ann Oncol. 2012 Jan;23(1):238-244. doi: 10.1093/annonc/mdr063. Epub 2011 Mar 29. Ann Oncol. 2012. PMID: 21447615 Free PMC article. Clinical Trial.

7

Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.

Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E; Princess Margaret Hospital Phase II Consortium; National Cancer Institute of Canada Clinical Trials Group Study. Siu LL, et al. Among authors: eisenhauer ea. J Clin Oncol. 2007 Jun 1;25(16):2178-83. doi: 10.1200/JCO.2006.07.6547. J Clin Oncol. 2007. PMID: 17538162 Clinical Trial.

8

Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).

Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Knox JJ, et al. Among authors: eisenhauer ea. Invest New Drugs. 2007 Oct;25(5):471-7. doi: 10.1007/s10637-007-9044-9. Epub 2007 Mar 28. Invest New Drugs. 2007. PMID: 17393073 Clinical Trial.

9

A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.

Baetz T, Eisenhauer E, Siu L, MacLean M, Doppler K, Walsh W, Fisher B, Khan AZ, de Alwis DP, Weitzman A, Brail LH, Moore M. Baetz T, et al. Among authors: eisenhauer e. Invest New Drugs. 2007 Jun;25(3):217-25. doi: 10.1007/s10637-006-9021-8. Epub 2006 Dec 5. Invest New Drugs. 2007. PMID: 17146732 Clinical Trial.

10

A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.

MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E. MacKenzie MJ, et al. Among authors: eisenhauer e. Ann Oncol. 2004 Apr;15(4):665-70. doi: 10.1093/annonc/mdh133. Ann Oncol. 2004. PMID: 15033677 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters